Intersect ENT Names Chief Commercial Officer

Menlo Park, Calif.-based Intersect ENT, which makes devices for patients with ear, nose and throat conditions, has named Chas McKhann as chief commercial officer.

“I am thrilled to welcome Chas to our team,” said Lisa Earnhardt, president and CEO of Intersect ENT. “He has spent much of his career helping companies identify and implement innovative growth strategies and has extensive experience commercializing products globally. Chas’ background, combined with his keen strategic mind and strong business acumen, will be critical as we seek to explore new growth levers such as building our global footprint as well as expanding our product offerings for ear, nose and throat physicians and their patients.”

“This is a unique opportunity to join a dynamic and innovative organization that is making patients’ lives better every day,” said McKhann. “Intersect has done a wonderful job of developing and commercializing products to help patients suffering from chronic sinusitis and give physicians the tools for better outcomes. I am excited to work with Lisa and the team to build on this strong foundation and help fully realize the potential of Intersect’s multiple avenues for growth and expansion.”

McKhann has more than two decades of experience in developing and commercializing successful medical technologies. Most recently, he served as a director in the strategy consulting practice at Monitor Deloitte, where he worked with global medical device manufacturers to create innovative growth strategies and to design new commercial models to compete effectively in a rapidly changing healthcare landscape. Previously, McKhann served as the CEO of a medical device start up focused on developing a new therapy for patients with sleep apnea, a condition treated by ear, nose, and throat surgeons. McKhann also previously worked at Boston Scientific, where he served as worldwide vice president of marketing, cardiac rhythm management and vice president of marketing and general manager, revascularization franchise, cardiac surgery. Prior to Boston Scientific, he served as director of marketing at Cordis, a Johnson & Johnson company, where he was responsible for the commercialization of the Cypher drug eluting stent. Earlier in his career, McKhann was a consultant in McKinsey & Company’s pharmaceuticals and medical products practice. McKhann holds a B.A. and an MBA from Stanford University.